MCID: PLY018
MIFTS: 60

Polycythemia

Categories: Rare diseases, Blood diseases, Immune diseases, Genetic diseases

Aliases & Classifications for Polycythemia

Summaries for Polycythemia

MalaCards based summary : Polycythemia, also known as polycythemia vera, is related to acquired polycythemia and autosomal dominant secondary polycythemia. An important gene associated with Polycythemia is CD177 (CD177 Molecule), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Zinc and Epinephrine have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and myeloid, and related phenotypes are cellular and growth/size/body region

Wikipedia : 72 Polycythemia (also known as polycythaemia or polyglobulia) is a disease state in which the hematocrit... more...

Related Diseases for Polycythemia

Diseases in the Polycythemia family:

Primary Polycythemia Acquired Polycythemia
Polycythemia Due to Hypoxia Autosomal Dominant Secondary Polycythemia

Diseases related to Polycythemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 302)
# Related Disease Score Top Affiliating Genes
1 acquired polycythemia 33.8 EPO EPOR JAK2
2 autosomal dominant secondary polycythemia 33.3 EGLN1 EPAS1
3 primary polycythemia 32.4 EGLN1 EPAS1 EPO EPOR IL3 JAK2
4 hemangioblastoma 32.2 EPO EPOR VHL
5 erythrocytosis, familial, 1 32.2 EPO EPOR IL3 JAK2 STAT5A THPO
6 erythrocytosis, familial, 2 32.0 EGLN1 EPAS1 EPO EPOR HIF1A VHL
7 myeloproliferative neoplasm 31.7 CALR JAK2 MPL TET2
8 budd-chiari syndrome 31.6 CALR F5 JAK2 MPL
9 polycythemia vera 30.8 CALR CD177 EPO EPOR F5 IL3
10 splenomegaly 30.4 EPO JAK2 MPL
11 hypoxia 29.9 EGLN1 EPAS1 HIF1A VHL
12 thrombocytosis 29.4 EPO IL3 JAK2 MPL TET2 THPO
13 pancytopenia 29.3 EPO MPL THPO
14 refractory anemia 29.1 EPO IL3 JAK2 MPL TET2
15 thalassemia 28.9 EPO HBB TFRC
16 iron deficiency anemia 28.7 EPO TFRC THPO
17 essential thrombocythemia 28.7 CALR CD177 EPO EPOR IL3 JAK2
18 myelofibrosis 28.7 CALR CD177 EPO IL3 JAK2 MPL
19 leukemia, acute myeloid 28.5 IL3 JAK2 KITLG MPL STAT5A TET2
20 leukemia, chronic myeloid 28.1 CD177 EPO IL3 JAK2 KITLG MPL
21 deficiency anemia 27.2 EPO EPOR HBB HIF1A IL3 TFRC
22 myelodysplastic syndrome 26.4 EPO EPOR IL3 JAK2 KITLG MPL
23 stress polycythemia 12.1
24 multiple paragangliomas associated with polycythemia 12.0
25 erythropoietin polycythemia 12.0
26 dystonia/parkinsonism, hypermanganesemia, polycythemia, and chronic liver disease 11.9
27 hypermanganesemia with dystonia 1 11.9
28 physiological polycythemia 11.9
29 dehydration polycythemia 11.9
30 autosomal recessive secondary polycythemia not associated with vhl gene 11.9
31 polycythemia due to hypoxia 11.8
32 plethora of newborn 11.3
33 erythromelalgia 11.2
34 aquagenic pruritus 11.2
35 hypermanganesemia with dystonia 11.2
36 chronic mountain sickness 11.2
37 hepatopulmonary syndrome 11.2
38 pseudopolycythaemia 11.1
39 fumarase deficiency 10.8
40 hemoglobin, high altitude adaptation 10.8
41 leiomyoma 10.8
42 pulmonary arterio-veinous fistula 10.8
43 chromosome 5q deletion syndrome 10.3 EPO TET2
44 fumarate hydratase deficiency 10.3 HIF1A VHL
45 transient erythroblastopenia of childhood 10.3 EPO KITLG
46 complement hyperactivation, angiopathic thrombosis, and protein-losing enteropathy 10.3
47 thrombosis 10.3
48 retinitis pigmentosa and erythrocytic microcytosis 10.3 EPO IL3 JAK2
49 leukemia 10.3
50 pyridoxine-responsive sideroblastic anemia 10.2 HBB TET2

Graphical network of the top 20 diseases related to Polycythemia:



Diseases related to Polycythemia

Symptoms & Phenotypes for Polycythemia

MGI Mouse Phenotypes related to Polycythemia:

43 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.26 HIF1A MPL STAT5A JAK2 TET2 KITLG
2 growth/size/body region MP:0005378 10.25 HIF1A MPL STAT5A JAK2 TET2 KITLG
3 hematopoietic system MP:0005397 10.25 STAT5A JAK2 TET2 KITLG TFRC MPL
4 cardiovascular system MP:0005385 10.24 HIF1A TET2 KITLG F5 EPAS1 VHL
5 embryo MP:0005380 10.23 JAK2 KITLG TFRC MPL F5 EPAS1
6 homeostasis/metabolism MP:0005376 10.21 MPL STAT5A JAK2 KITLG HIF1A F5
7 immune system MP:0005387 10.17 MPL STAT5A JAK2 TET2 KITLG TFRC
8 liver/biliary system MP:0005370 9.93 STAT5A JAK2 TET2 KITLG TFRC F5
9 integument MP:0010771 9.91 HIF1A STAT5A JAK2 KITLG EGLN1 TFRC
10 mortality/aging MP:0010768 9.8 HIF1A MPL STAT5A JAK2 TET2 KITLG
11 normal MP:0002873 9.23 HIF1A STAT5A JAK2 TET2 EPOR TFRC

Drugs & Therapeutics for Polycythemia

Drugs for Polycythemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 291)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Zinc Approved, Investigational Phase 4 7440-66-6 32051 23994
2
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
3
Acetazolamide Approved, Vet_approved Phase 4,Phase 1,Phase 2 59-66-5 1986
4 Racepinephrine Approved Phase 4 329-65-7
5
Lactitol Investigational Phase 4 585-86-4 3871
6 insulin Phase 4
7 diuretics Phase 4,Phase 1,Phase 2
8 Natriuretic Agents Phase 4,Phase 1,Phase 2
9 Epinephryl borate Phase 4
10 Anticonvulsants Phase 4,Phase 1,Phase 2
11 Hypoglycemic Agents Phase 4,Phase 2,Phase 3
12 Insulin, Globin Zinc Phase 4
13 Carbonic Anhydrase Inhibitors Phase 4,Phase 1,Phase 2
14
Carboplatin Approved Phase 2, Phase 3,Phase 1 41575-94-4 10339178 38904 498142
15
Cyclophosphamide Approved, Investigational Phase 2, Phase 3,Phase 1 50-18-0, 6055-19-2 2907
16
Fludarabine Approved Phase 2, Phase 3, Phase 1 21679-14-1, 75607-67-9 30751
17
Busulfan Approved, Investigational Phase 2, Phase 3,Phase 1 55-98-1 2478
18
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
19
Testosterone Approved, Investigational Phase 3 58-22-0 6013
20
Aspirin Approved, Vet_approved Phase 3,Phase 2 50-78-2 2244
21
Etoposide Approved Phase 2, Phase 3,Phase 1 33419-42-0 36462
22
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
23
Melphalan Approved Phase 2, Phase 3, Phase 1 148-82-3 460612 4053
24
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
25
Morphine Approved, Investigational Phase 3 57-27-2 5288826
26
Metformin Approved Phase 2, Phase 3 657-24-9 4091 14219
27
Hydroxyurea Approved Phase 3,Phase 2,Phase 1 127-07-1 3657
28
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
29
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
30
Ondansetron Approved Phase 3,Phase 1,Phase 2 99614-02-5 4595
31
Danazol Approved Phase 3,Phase 2 17230-88-5 28417
32 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
33
Anagrelide Approved Phase 3,Phase 2 68475-42-3 2182
34
Lenalidomide Approved Phase 3,Phase 2 191732-72-6 216326
35
Benzocaine Approved, Investigational Phase 3,Phase 1,Phase 2 1994-09-7, 94-09-7 2337
36
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
37
Dextromethorphan Approved Phase 3 125-71-3 5362449 5360696
38
Peginterferon alfa-2a Approved, Investigational Phase 3,Phase 2,Phase 1 198153-51-4 5360545
39
Peginterferon alfa-2b Approved Phase 3,Phase 1,Phase 2 215647-85-1, 99210-65-8
40
Caspofungin Approved Phase 3,Phase 2 162808-62-0, 179463-17-3 2826718 468682
41
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
42 Pomalidomide Approved Phase 3,Phase 1,Phase 2 19171-19-8
43 tannic acid Approved, Nutraceutical Phase 3,Phase 1,Phase 2
44
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
45
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
46 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
47 Analgesics Phase 3,Phase 2,Phase 1
48 Alkylating Agents Phase 2, Phase 3,Phase 1
49 Central Nervous System Depressants Phase 3,Phase 1,Phase 2
50 Neurotransmitter Agents Phase 3,Phase 2

Interventional clinical trials:

(show top 50) (show all 284)

# Name Status NCT ID Phase Drugs
1 Treatment of High Altitude Polycythemia by Acetazolamide Completed NCT00424970 Phase 4 acetazolamide
2 Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) Completed NCT01558739 Phase 4 INC424
3 Investigating the Accuracy of the Home Glucose Monitors in Hypoglycemia Completed NCT01013402 Phase 4 Human insulin;Human Insulin
4 CINC424A2X01B Rollover Protocol Recruiting NCT02386800 Phase 4 Ruxolitinib
5 Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes Withdrawn NCT00160485 Phase 4 Glyburide;Insulin
6 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 Randomized Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study Completed NCT01632904 Phase 3 Ruxolitinib;Hydroxyurea (HU);HU-placebo;Ruxolitinib-placebo
8 Study to Assess the Self-administration of AOP2014 Using a Pen, Developed for the Treatment of Polycythemia Vera Patients Completed NCT02523638 Phase 3 Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
9 Pegylated Interferon Alpha-2b Versus Hydroxyurea in Polycythemia Vera Completed NCT01949805 Phase 3 Peg-P-IFN-alpha-2b (AOP2014);Hydroxyurea
10 Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Completed NCT01259856 Phase 3 PEGASYS;Hydroxyurea;Aspirin
11 A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Completed NCT02087059 Phase 3 Ruxolitinib
12 INC424 for Patients With Primary Myelofibrosis, Post Polycythemia Myelofibrosis or Post-essential Thrombocythemia Myelofibrosis. Completed NCT01493414 Phase 3 INC424
13 Controlled Myelofibrosis Study With Oral Janus-associated Kinase (JAK) Inhibitor Treatment-II: The COMFORT-II Trial Completed NCT00934544 Phase 3 INC424/INCB018424;Best Available Therapy (BAT)
14 COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I Trial Completed NCT00952289 Phase 3 Ruxolitinib;Placebo
15 Phase III Study of SAR302503 in Intermediate-2 and High Risk Patients With Myelofibrosis Completed NCT01437787 Phase 3 SAR302503;Placebo
16 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
17 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
18 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
19 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
20 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
21 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
22 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
23 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
24 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
25 Metformin in Obese Non-diabetic Pregnant Women Completed NCT01273584 Phase 2, Phase 3 Metformin;Placebo
26 Expanded Treatment Protocol (ETP) of Ruxolitinib in Patients With Polycythemia Vera Who Are Hydroxyurea Resistant or Intolerant and for Whom no Treatment Alternatives Are Available. Recruiting NCT02292446 Phase 3 Ruxolitinib
27 AOP2014 vs. BAT in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study. Active, not recruiting NCT02218047 Phase 3 Pegylated-Proline-interferon alpha-2b;Best available therapy (BAT)
28 Ruxolitinib Efficacy and Safety in Patients With HU Resistant or Intolerant Polycythemia Vera vs Best Available Therapy. Active, not recruiting NCT02038036 Phase 3 Best Available Therapy;ruxolitinib
29 Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial) Active, not recruiting NCT01243944 Phase 3 ruxolitinib tablets
30 Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF Active, not recruiting NCT02101268 Phase 3 Momelotinib;Best Available Therapy (BAT)
31 Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis Active, not recruiting NCT01969838 Phase 3 Momelotinib;Ruxolitinib;Placebo to match momelotinib;Placebo to match ruxolitinib
32 A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms Active, not recruiting NCT01387763 Phase 3 PegIntron;Pegasys;PegIntron;Pegasys;Hydrea
33 Phase-3 Double-Blind, Placebo-Controlled Study of Pomalidomide in Persons With Myeloproliferative-Neoplasm-Associated Myelofibrosis and RBC-Transfusion-Dependence Myelofibrosis and RBC-Transfusion-Dependence Active, not recruiting NCT01178281 Phase 3 Pomalidomide 0.5 mg;Placebo
34 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
35 Large-scale Trial Testing the Intensity of CYTOreductive Therapy in Polycythemia Vera (PV) Terminated NCT01645124 Phase 3 Hydroxyurea
36 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia Terminated NCT02055781 Phase 3 Pacritinib;Best Available Therapy
37 Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Terminated NCT01773187 Phase 3 Pacritinib;Best Available Therapy
38 H-36731: Finasteride in Management of Elevated Red Blood Cells Withdrawn NCT02548117 Phase 3 Finasteride
39 A Study of the Efficacy of MK-0683 in Patients With Polycythaemia Vera and Essential Thrombocythaemia Unknown status NCT00866762 Phase 2 HDAC inhibitor (MK-0683)
40 LBH589 (Panobinostat) for the Treatment of Myelofibrosis Unknown status NCT01298934 Phase 1, Phase 2 LBH589
41 CEP-701 (Lestaurtinib) in Myelofibrosis Unknown status NCT00668421 Phase 1, Phase 2 CEP-701 (Lestaurtinib)
42 Phase II Study of GIVINOSTAT (ITF2357) in Combination With Hydroxyurea in Polycythemia Vera Completed NCT00928707 Phase 2 GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea;GIVINOSTAT (ITF2357) 50 mg b.i.d. + MTD Hydroxyurea
43 A Two-part Study to Assess the Safety and Preliminary Efficacy of Givinostat in Patients With Polycythemia Vera Completed NCT01901432 Phase 1, Phase 2 Givinostat
44 Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET) Completed NCT01259817 Phase 2 PEGASYS;Aspirin
45 Treatment of Polycythemia Vera With Gleevec Completed NCT01120821 Phase 2 Gleevec
46 Efficacy and Safety of Pegylated Interferon Alfa in Polycythemia Vera Completed NCT00241241 Phase 2 pegylated interferon-alfa 2a
47 Effects of Imatinib Mesylate in Polycythemia Vera Completed NCT00430066 Phase 2 Imatinib Mesylate
48 Open Label Study to Evaluate the Activity of Imetelstat in Patients With Essential Thrombocythemia or Polycythemia Vera Completed NCT01243073 Phase 2 Imetelstat
49 Open-Label Study of Oral CEP-701 (Lestaurtinib) in Patients With Polycythemia Vera or Essential Thrombocytosis Completed NCT00586651 Phase 2 lestaurtinib
50 Safety Study of Pegylated Interferon Alpha 2b to Treat Polycythemia Vera Completed NCT01193699 Phase 1, Phase 2 PEG-P-INF alpha-2b (P1101)

Search NIH Clinical Center for Polycythemia

Inferred drug relations via UMLS 69 / NDF-RT 47 :


Cochrane evidence based reviews: polycythemia

Genetic Tests for Polycythemia

Genetic tests related to Polycythemia:

# Genetic test Affiliating Genes
1 Polycythemia 28
2 Polycythaemia 28

Anatomical Context for Polycythemia

MalaCards organs/tissues related to Polycythemia:

38
Bone, Bone Marrow, Myeloid, Liver, T Cells, Testes, Kidney

Publications for Polycythemia

Articles related to Polycythemia:

(show top 50) (show all 1129)
# Title Authors Year
1
Prognostic risk model for patients with high-risk polycythemia vera and essential thrombocythemia. ( 29313725 )
2018
2
Severe Secondary Polycythemia in a Female-to-Male Transgender Patient While Using Lifelong Hormonal Therapy: A Patient's Perspective. ( 29396819 )
2018
3
Health Care Costs and Thromboembolic Events in Hydroxyurea-Treated Patients with Polycythemia Vera. ( 29290171 )
2018
4
Frequency of Polycythemia and Other Abnormalities in a Tibetan Herdsmen Population Residing in the Kham Area of Sichuan Province, China. ( 29338990 )
2018
5
Pulsatile flow of non-Newtonian blood fluid inside stenosed arteries: Investigating the effects of viscoelastic and elastic walls, arteriosclerosis, and polycythemia diseases. ( 29249336 )
2018
6
Ruxolitinib is effective and safe in Japanese patients with hydroxyurea-resistant or hydroxyurea-intolerant polycythemia vera with splenomegaly. ( 28956263 )
2018
7
Aquagenic Pruritus in Polycythemia Vera: Clinical Characteristics. ( 29437189 )
2018
8
Incidence of solid tumors in polycythemia vera treated with phlebotomy with or without hydroxyurea: ECLAP follow-up data. ( 29335456 )
2018
9
Bone marrow findings in blast phase of polycythemia vera. ( 29285580 )
2018
10
Distinguishing myelofibrosis from polycythemia vera and essential thrombocythemia: The utility of enumerating circulating stem cells with aberrant hMICL expression by flow cytometry. ( 29427319 )
2018
11
Polycythemia vera and essential thrombocythemia: algorithmic approach. ( 29194068 )
2018
12
Polycythemia vera treatment algorithm 2018. ( 29321547 )
2018
13
Non-driver mutations in patients with JAK2V617F-mutated polycythemia vera or essential thrombocythemia with long-term molecular follow-up. ( 29181548 )
2018
14
Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis. ( 29226426 )
2018
15
Association of subcutaneous testosterone pellet therapy with developing secondary polycythemia. ( 29205178 )
2017
16
Polycythemia vera: from new, modified diagnostic criteria to new therapeutic approaches. ( 28949941 )
2017
17
Mediastinal syndrome from plasmablastic lymphoma in human immunodeficiency virus and human herpes virus 8 negative patient with polycythemia vera: a case report. ( 28320457 )
2017
18
Pulmonary Hypertension Associated with Pulmonary Veno-occlusive Disease in Patients with Polycythemia Vera. ( 28824072 )
2017
19
Therapy of polycythemia vera: is it time to change? ( 29262518 )
2017
20
Pulmonary extra-medullary hematopoiesis and pulmonary hypertension from underlying polycythemia vera: a case series. ( 28680586 )
2017
21
The Amelioration of Myelofibrosis with Thrombocytopenia by a JAK1/2 Inhibitor, Ruxolitinib, in a Post-polycythemia Vera Myelofibrosis Patient with a JAK2 Exon 12 Mutation. ( 28674362 )
2017
22
Can color difference on the maternal side of the placenta distinguish between acute peripartum twin-twin transfusion syndrome and twin anemia-polycythemia sequence? ( 28864011 )
2017
23
European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. ( 28685840 )
2017
24
JAK2 exon 12 mutated polycythemia vera: Mayo-Careggi MPN Alliance study of 33 consecutive cases and comparison with JAK2V617F mutated disease. ( 29274140 )
2017
25
Tumor Lysis Syndrome after the Administration of Ruxolitinib in a Patient with Post-polycythemia Vera Myelofibrosis. ( 28794380 )
2017
26
Fibrotic progression in Polycythemia vera is associated with early concomitant driver-mutations besides JAK2. ( 28935989 )
2017
27
Loss of p53 induces leukemic transformation in a murine model of Jak2 V617F-driven polycythemia vera. ( 28068330 )
2017
28
Recurrent Twin-Twin Transfusion Syndrome (rTTTS) and Twin Anemia Polycythemia Sequence (TAPS) after fetoscopic laser surgery (FLS): size (of the cannula) does matter. ( 28925589 )
2017
29
Associations of high altitude polycythemia with polymorphisms in EPHA2 and AGT in Chinese Han and Tibetan populations. ( 28881807 )
2017
30
A phase 1 study of the Janus kinase 2 (JAK2)(V617F) inhibitor, gandotinib (LY2784544), in patients with primary myelofibrosis, polycythemia vera, and essential thrombocythemia. ( 28934680 )
2017
31
Progression of primary myelofibrosis to polycythemia vera: A case report. ( 28700486 )
2017
32
Alox5 Blockade Eradicates JAK2V617F-Induced Polycythemia Vera in Mice. ( 27784744 )
2017
33
Disease and treatment characteristics of polycythemia vera patients in Belgium: Results from a scientific survey. ( 29285836 )
2017
34
A reappraisal of the benefit-risk profile of hydroxyurea in polycythemia vera: A propensity-matched study. ( 28699191 )
2017
35
In the era of next generation sequencing, is the cytogenetic analysis still important in polycythemia vera? ( 28702402 )
2017
36
Erythromelalgia in patients with essential thrombocythemia and polycythemia vera. ( 27684959 )
2017
37
Can pegylated interferon improve the outcome of polycythemia vera patients? ( 28086927 )
2017
38
What are the current treatment approaches for patients with polycythemia vera and essential thrombocythemia? ( 29222296 )
2017
39
Aquagenic pruritus in polycythemia vera: a cross-sectional study. ( 29066270 )
2017
40
Epstein-Barr virus-positive mucocutaneous ulcer in a patient with polycythemia vera treated with oral hydroxyurea. ( 29139148 )
2017
41
A phase 2 study of momelotinib, a potent JAK1 and JAK2 inhibitor, in patients with polycythemia vera or essential thrombocythemia. ( 28622623 )
2017
42
The role of certain gene polymorphisms involved in the apoptotic pathways in polycythemia vera and essential thrombocytosis. ( 29068570 )
2017
43
From anemia to polycythemia in 4 weeks. ( 28878919 )
2017
44
Recurrent Cardiovascular Events Despite Antiplatelet Therapy in a Patient with Polycythemia Vera and Accelerated Platelet Turnover. ( 28860447 )
2017
45
Application of current prognostic models for primary myelofibrosis in the setting of post-polycythemia vera or post-essential thrombocythemia myelofibrosis. ( 28819279 )
2017
46
Transcriptome reveals the overexpression of a kallikrein gene cluster (KLK1/3/7/8/12) in the Tibetans with high altitude-associated polycythemia. ( 28000848 )
2017
47
Anti-Platelet Factor 4/Heparin Antibody Formation Occurs Endogenously and at Unexpected High Frequency in Polycythemia Vera. ( 28698883 )
2017
48
Patients with post-essential thrombocythemia and post-polycythemia vera differ from patients with primary myelofibrosis. ( 28601551 )
2017
49
Erythrocytosis caused by giant chromophobe renal cell carcinoma: a case report indicating a 9-year misdiagnosis of polycythemia vera. ( 28877745 )
2017
50
Risk factors for arterial versus venous thrombosis in polycythemia vera: a single center experience in 587 patients. ( 29282357 )
2017

Variations for Polycythemia

Copy number variations for Polycythemia from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 251119 9 25500000 28100000 Mutation JAK2 polycythaemia
2 251120 9 25500000 28100000 Mutation V617F polycythaemia
3 253987 9 4985245 5128183 Mutation JAK2 polycythaemia

Expression for Polycythemia

Search GEO for disease gene expression data for Polycythemia.

Pathways for Polycythemia

Pathways related to Polycythemia according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.55 EPO EPOR IL3 JAK2 KITLG MPL
2
Show member pathways
13.44 EPO EPOR IL3 JAK2 KITLG MPL
3
Show member pathways
13.21 CD177 F5 HBB IL3 JAK2 MPL
4 12.47 IL3 JAK2 KITLG MPL STAT5A
5
Show member pathways
12.38 EGLN1 EPAS1 HIF1A STAT5A VHL
6 12.04 EGLN1 EPAS1 EPO EPOR HIF1A IL3
7
Show member pathways
11.94 EPO EPOR IL3 JAK2 KITLG STAT5A
8
Show member pathways
11.88 EPO EPOR IL3 JAK2 MPL STAT5A
9 11.87 EPO IL3 KITLG MPL THPO
10
Show member pathways
11.8 EPO EPOR JAK2 STAT5A
11 11.76 EPO EPOR IL3 JAK2 STAT5A
12
Show member pathways
11.74 EPAS1 HIF1A VHL
13 11.72 EGLN1 EPO HIF1A TFRC VHL
14 11.62 EPO EPOR IL3 KITLG TFRC THPO
15 11.61 EGLN1 EPO HIF1A TFRC
16 11.58 HIF1A JAK2 STAT5A
17 11.51 EGLN1 EPO HIF1A VHL
18 11.43 EPO IL3 KITLG
19 11.42 EPO IL3 KITLG STAT5A
20
Show member pathways
11.39 EPO EPOR JAK2
21 11.29 EGLN1 EPO HIF1A
22 11.2 EGLN1 EPAS1 EPO VHL
23 11.19 JAK2 MPL STAT5A THPO
24 10.91 JAK2 STAT5A
25 10.85 EPAS1 VHL
26 10.79 HIF1A VHL

GO Terms for Polycythemia

Cellular components related to Polycythemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.61 CALR EPO EPOR F5 HBB IL3
2 extracellular space GO:0005615 9.23 CALR EPO F5 HBB IL3 KITLG
3 endocytic vesicle lumen GO:0071682 9.16 CALR HBB

Biological processes related to Polycythemia according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.97 CALR EPO IL3 JAK2 KITLG
2 blood coagulation GO:0007596 9.83 CD177 F5 HBB JAK2
3 response to hypoxia GO:0001666 9.78 EGLN1 EPAS1 EPO HIF1A
4 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.73 IL3 JAK2 KITLG
5 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.72 EPO IL3 JAK2
6 cellular iron ion homeostasis GO:0006879 9.71 EGLN1 HIF1A TFRC
7 cytokine-mediated signaling pathway GO:0019221 9.67 EPOR IL3 JAK2 MPL
8 JAK-STAT cascade involved in growth hormone signaling pathway GO:0060397 9.58 JAK2 STAT5A
9 erythrocyte differentiation GO:0030218 9.58 EPAS1 EPO JAK2
10 oxygen homeostasis GO:0032364 9.51 EGLN1 HIF1A
11 regulation of transcription from RNA polymerase II promoter in response to oxidative stress GO:0043619 9.49 EPAS1 HIF1A
12 hemoglobin biosynthetic process GO:0042541 9.46 EPO HIF1A
13 positive regulation of hematopoietic stem cell proliferation GO:1902035 9.43 KITLG THPO
14 embryonic hemopoiesis GO:0035162 9.33 HIF1A IL3 KITLG
15 erythropoietin-mediated signaling pathway GO:0038162 9.32 EPO EPOR
16 thrombopoietin-mediated signaling pathway GO:0038163 9.26 MPL THPO
17 positive regulation of DNA replication GO:0045740 9.26 CALR EPO IL3 KITLG
18 regulation of transcription from RNA polymerase II promoter in response to hypoxia GO:0061418 9.02 EGLN1 EPAS1 EPO HIF1A VHL

Molecular functions related to Polycythemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.55 CALR CD177 EGLN1 EPAS1 EPO EPOR
2 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.33 IL3 JAK2 KITLG
3 cytokine activity GO:0005125 9.26 EPO IL3 KITLG THPO

Sources for Polycythemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....